Glutamatergic fine tuning with ADX-10059: A novel therapeutic approach for migraine?

Expert Opinion on Investigational Drugs

Volumn 19, Issue 4, 2010, Pages 555-561

  Marin, Juana C A ^a   Goadsby, Peter J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UCSF Headache Center   (United States)

Author keywords

Acute treatment; Allosteric; Brain; Excitatory; Glutamate; Metabotropic; Migraine; Modulator; Preventive treatment; Primary headaches; Trigeminal transmission

Indexed keywords

ADX 10059; AMITRIPTYLINE; ANALGESIC AGENT; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; FLUNARIZINE; GABAPENTIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5; METHYSERGIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PIZOTIFEN; PLACEBO; PROPRANOLOL; SEROTONIN 1B AGONIST; SUMATRIPTAN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID; AMINO ACID RECEPTOR AFFECTING AGENT; GASTROINTESTINAL AGENT; GRM5 PROTEIN, HUMAN; METABOTROPIC RECEPTOR; NEW DRUG;

AREA UNDER THE CURVE; ASTHENIA; BIOCHEMISTRY; CLINICAL TRIAL; CONCENTRATION LOSS; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEMATOLOGY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MIGRAINE WITH AURA; NAUSEA; NERVE CELL PLASTICITY; NONHUMAN; NYSTAGMUS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; THALAMUS VENTRAL NUCLEUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIGEMINAL NERVE; VERTIGO; VISUAL DISORDER; VITAL SIGN; VOMITING; AGONISTS; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MIGRAINE DISORDERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUGS, INVESTIGATIONAL; EXCITATORY AMINO ACID AGENTS; GASTROINTESTINAL AGENTS; HUMANS; MIGRAINE DISORDERS; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 77952473377     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003691832     Document Type: Review

References (55)

1. Lance JW, Goadsby PJ. Mechanism and management of headache. 7th edition. Elsevier New York; 2005
2. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):1-160
3. Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the landmark study. Headache 2004;44:856-864
4. Stewart WF, Simon D, Shechter A, Lipton RB. Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol 1995;48:269-280
5. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27
6. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-2454
7. Menken M, Munsat TL, Toole JF. The global burden of disease study-implications for neurology. Arch Neurol 2000;57:418-420
8. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002;346:257-270
9. Goadsby PJ, Charbit AR, Andreou AP, et al. Neurobiology of migraine. Neuroscience 2009;161:327-341
10. Goadsby PJ, Bartsch T, Dodick DW. Occipital nerve stimulation (ONS) for headache: mechanisms and efficacy. Headache 2008;48:313-318
11. Ferrari MD, Goadsby PJ. Migraine as a cerebral ionopathy with abnormal central sensory processing. In: Gilman S, editor, Neurobiology of disease. Elsevier, New York; 2007. p. 333-348
12. Stovner LJ, Tronvik E, Hagen K. New drugs for migraine. J Headache Pain 2009;10:395-406
13. Goadsby PJ. Emerging therapies for migraine. Nat Clin Pract Neurol 2007;3:610-619
14. Goadsby PJ. Calcitonin gene-related peptide (CGRP) antagonists and migraine-is this a new era? Neurology 2008;70:1300-1301
15. Goadsby PJ, Schoenen J, Ferrari MD, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006;26:1168-1170
16. Debanne D, Daoudal G, Sourdet V, Russier M. Brain plasticity and ion channels. J Physiol Paris 2003;97:403-414
17. Perez-Otano I, Ehlers MD. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci 2005;28:229-238
18. Asztely F, Gustafsson BI. Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Mol Neurobiol 1996;12:1-11
19. Weiler IJ, Greenough WT. Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci USA 1993;90:7168-7171
20. Albin RL, Makowiec RL, Hollingsworth ZR, et al. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 1992;46:35-48
21. Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 1992;322:121-135
22. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution on the mRNA for a metabolic glutamate receptor, mGluR3, in the rat brain: an in situ hybridization study. J Comp Neurol 1993;335:252-266
23. Testa CM, Standaert DG, Young AB, Penney JB. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 1994;14:3005-3018
24. Tallaksen-Greene SJ, Kaatz KW, Romano C, Albin RL. Localization of mGlur1-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res 1998;780:210-217
25. Romano C, Sesma MA, McDonald CT, et al. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995;355:455-469
26. Abe T, Sugihara H, Nawa H, et al. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem 1992;267:13361-13368
27. Shigemoto R, Nomura S, Ohishi H, et al. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 1993;163:53-57
28. Liang Y-C, Huang C-C, Hsu K-S. Characterization of the long term potentiation of primary afferent transmission at trigeminal synapses of juvenile rats:essential role of subType 5 or metabotropic glutamate receptors. Pain 2005;114:417-428
29. Frisby CL, Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005;129:995-1004
30. Greenamyre JT, Young AB, Penney JB. Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. J Neurosci 1984;4:2133-2144
31. Kai-Kai MA, Howe R. Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat. Histochem J 1991;23:171-179
32. Tallaksen-Greene SJ, Young AB, Penney JB, Beitz AJ. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neuroscience Lett 1992;141:79-83
33. Halpain S, Wieczorek CM, Rainbow TC. Localization of L-glutamate receptors in rat brain by quantitative autoradiography. J Neurosci 1984;4:2247-2258
34. Watanabe M, Mishina M, Inoue Y. Distinct gene expression of the N-methyl-D-aspartate receptor channel subunit in peripheral neurons of the mouse sensory ganglia and adrenal gland. Neurosci Lett 1994;165:183-186
35. Sahara Y, Noro N, Iida Y, et al. Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 1997;17:6611-6620
36. Tamaru Y, Nomura S, Mizuno N, Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre-and postsynaptic sites. Neuroscience 2001;106:481-503
37. Hill RG, Salt TE. An iontophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. J Physiol 1982;327:65-78
38. Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res 2000;875:119-124
39. Bereiter DA, Bereiter DF, Hathaway CB. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomic responses to corneal stimulation in the rat. Pain 1996;64:179-189
40. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache 2006;46(Suppl 1):S39-44
41. Xiao Y, Richter JA, Hurley JH. Release of glutamate and CGRP from trigeminal ganglion neurons: role of calcium channels and 5-HT1 receptor signaling. Mol Pain 2008;4:12
42. Ma QP. Co-localisation of 5HT1B/1D/1F receptors and glutamate in trigeminal ganglion in rats. Neuroreport 2001;12:1589-1591
43. Silva E, Quinones B, Freund N, et al. Extracellular glutamate, aspartate and arginine increase in the ventral posterolateral thalamic nucleus during nociceptive stimulation. Brain Res 2001;923:45-49
44. Salt TE. Glutamate receptor functions in sensory relay in the thalamus. Philos Trans R Soc Lond B Biol Sci 2002;357:1759-1766
45. Award H, Hubert GW, Smith Y, et al. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000;20:7871-7879
46. Nicolodi M, Sicutieri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Pharmacol Res 1995;15:181-189
47. Kaube H, Herzog J, Kaufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000;55:139-141
48. Storer RJ, Goadsby PJ. N-Methyl-d-Aspartate receptor channel complex blockers including memantine and magnesium inhibit nociceptive traffic in the trigeminocervical complex of the rat. Cephalalgia 2009;29(Suppl 1):135
49. Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 2007;8:248-250
50. Goadsby PJ, Keywood C. Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute treatment of migraine. Neurology 2009;72(Suppl 1):A285
51. Saper J, Goadsby PJ, Silberstein S, Dodick DW. Occipital nerve stimulation (ONS) for treatment of intractable chronic migraine (ICM): 3-Month Results from the ONSTIM Feasibility Study. Neurology 2009;72(Suppl 3):A252
52. Lipton RB, Goadsby PJ, Cady RK, et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009;29(Suppl 1):30
53. Dodick DW, Smith TR, Becker WJ, et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase. Cephalalgia 2009;29(Suppl 1):29
54. Reuter U, Pilgrim AJ, Diener H-C, et al. COL-144, a selective 5-HT1F agonist, for the treatment of migraine attacks. Cephalalgia 2009;29:122
55. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-2123